Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment

Journal of Clinical Investigation

Volumn 126, Issue 12, 2016, Pages 4417-4429

  Starobinets, Hanna ^a   Ye, Jordan ^a   Broz, Miranda ^a   Barry, Kevin ^a   Goldsmith, Juliet ^a   Marsh, Timothy ^a   Rostker, Fanya ^a   Krummel, Matthew ^a   Debnath, Jayanta ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTIMALARIAL AGENT; CHLOROQUINE; DOXORUBICIN; HYDROXYCHLOROQUINE; MEPACRINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CELL LYSATE; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; EMBRYO; GENETIC BACKGROUND; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; VIRUS PARTICLE; ANIMAL; CELLULAR IMMUNITY; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIMALARIALS; AUTOPHAGY; CELL LINE, TUMOR; FEMALE; IMMUNITY, CELLULAR; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA; MICE; MICE, TRANSGENIC; T-LYMPHOCYTES;

EID: 85002609422     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85705     Document Type: Article

References (41)

1. Kaur J, Debnath J. Autophagy at the crossroads of catabolism and anabolism. Nat Rev Mol Cell Biol. 2015;16(8):461-472.
2. Kenific CM, Debnath J. Cellular and metabolic functions for autophagy in cancer cells. Trends Cell Biol. 2015;25(1):37-45.
3. White E. The role for autophagy in cancer. J Clin Invest. 2015;125(1):42-46.
4. Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy in cancer. Oncogene. 2016;35(1):1-11.
5. Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther. 2011;10(9):1533-1541.
6. Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Au tophagy. 2014;10(8):1415-1425.
7. Mahalingam D, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerabili-ty, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy. 2014;10(8):1403-1414.
8. Rangwala R, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxy-chloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autopha-gy. 2014;10(8):1391-1402.
9. Rangwala R, et al. Phase I trial of hydroxychlo-roquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10(8):1369-1379.
10. Rosenfeld MR, et al. A phase I/II trial of hydroxy-chloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy. 2014;10(8):1359-1368.
11. Vogl DT, et al. Combined autophagy and pro-teasome inhibition: a phase 1 trial of hydroxy-chloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy. 2014;10(8):1380-1390.
12. Wolpin BM, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychlo-roquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19(6):637-638.
13. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosur-veillance. Immunity. 2013;39(1):74-88.
14. Sistigu A, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20(11):1301-1309.
15. Garg AD, Martin S, Golab J, Agostinis P. Danger signalling during cancer cell death: origins, plasticity and regulation. Cell Death Differ. 2014;21(1):26-38.
16. Michaud M, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334(6062):1573-1577.
17. Michaud M, Xie X, Bravo-San Pedro JM, Zitvogel L, White E, Kroemer G. An autophagy-depen-dent anticancer immune response determines the efficacy of melanoma chemotherapy. Onco-immunology. 2014;3(7):e944047.
18. Gupta A, et al. Autophagy inhibition and anti-malarials promote cell death in gastrointestinal stromal tumor (GIST). Proc Natl Acad Sci USA. 2010;107(32):14333-14338.
19. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734-1736.
20. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
21. Brahmer JR, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, phar-macodynamics, and immunologic correlates. J Clin O ncol. 2010;28(19):3167-3175.
22. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
23. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
24. Wolchok JD, et al. Nivolumab plus ipilim-umab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
25. Schumacher TN, Schreiber RD. Neoanti-gens in cancer immunotherapy. Science. 2015;348(6230):69-74.
26. Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12(4):307-313.
27. Vanneman M, Dranoff G. Combining immuno-therapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12(4):237-251.
28. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
29. Baaten BJ, Li CR, Deiro MF, Lin MM, Linton PJ, Bradley LM. CD44 regulates survival and memory development in Th1 cells. Immunity. 2010;32(1):104-115.
30. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17-27.
31. Reinhardt RL, Liang HE, Locksley RM. Cyto-kine-secreting follicular T cells shape the antibody repertoire. Nat Immunol. 2009;10(4): 385-393.
32. Manic G, Obrist F, Kroemer G, Vitale I, Galluzzi L. Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol. 2014;1(1):e29911.
33. Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oxi-dative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene. 2016;35(22):2913-2922.
34. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001;Chapter 20:Unit 20.1.
35. Pulaski BA, Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr Protoc Immunol. 2001; chapter 20: unit 20.2.
36. Salmeron G, Lipsky PE. Immunosuppres-sive potential of antimalarials. Am J Med. 1983;75(1A):19-24.
37. Fox RI. Mechanism of action of hydroxychloro-quine as an antirheumatic drug. Semin Arthritis Rheum. 1993;23(2 suppl 1):82-91.
38. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol. 2008;8(8):607-618.
39. Demachi-Okamura A, Torikai H, Akatsuka Y, Miyoshi H, Yoshimori T, Kuzushima K. Autoph-agy creates a CTL epitope that mimics tumor-as-sociated antigens. PLoS One. 2012;7(10):e47126.
40. Fung C, Lock R, Gao S, Salas E, Debnath J. Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell. 2008;19(3):797-806.
41. Engelhardt JJ, et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell. 2012;21(3):402-417.